Cite
HARVARD Citation
Gill, U. et al. (n.d.). PTU-117 Sequential NUC therapy following pegylated interferon provides a greater decline in HBSAG and potentially offers a treatment advantage over current therapies. Gut. pp. A113-A114. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Gill, U. et al. (n.d.). PTU-117 Sequential NUC therapy following pegylated interferon provides a greater decline in HBSAG and potentially offers a treatment advantage over current therapies. Gut. pp. A113-A114. [Online].